Pyxis Oncology, Inc. announced a private placement to issue 8,849,371 shares of its common stock at a price of $4.78 per share for the gross proceeds of $42,299,993.38 and pre-funded warrants to purchase 1,611,215 shares of its common stock at a price per pre-funded warrant of $4.779 for the gross proceeds of $7,699,996.485 aggregate gross proceeds of $9,999,989.865 on February 26, 2024. The transaction will include participation from new and existing institutional investors, including Deep Track Capital, Ridgeback Capital Investments L.P., Blue Owl Healthcare Opportunities, Laurion Capital Management, and StemPoint Capital L.P. along with group of institutional and accredited healthcare specialist investors. The private placement is expected to close on or about February 29, 2024, subject to customary closing conditions.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.19 USD | +0.96% | -2.33% | +132.78% |
14/05 | Earnings Flash (PYXS) PYXIS ONCOLOGY Posts Q1 Revenue $16.1M | MT |
14/05 | Pyxis Oncology, Inc. Appoints Stephen Worsley as its Senior Vice President | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+132.78% | 247M | |
+9.58% | 115B | |
+12.41% | 107B | |
-3.55% | 21.6B | |
-12.38% | 22.31B | |
-6.45% | 19.19B | |
-3.35% | 18.23B | |
-38.57% | 17.62B | |
+7.51% | 14.26B | |
+35.67% | 12.37B |
- Stock Market
- Equities
- PYXS Stock
- News Pyxis Oncology, Inc.
- Pyxis Oncology, Inc. announced that it expects to receive $49.999989 million in funding from Blue Owl Healthcare Opportunities, StemPoint Capital LP, Deep Track Capital, LP, Laurion Capital Management LP, Ridgeback Capital Management LLC and another investors